Medical Excellence Capital — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).
BiotechDeep TechMedical DevicesNissequogue, US
Valerie Estess(Director)
BoardJohn Prufeta(Director)inJoni Mancini(Executive Officer)inBrent R. Stockwell(Chair of the Department of Biological Science, Professor at Columbia University)Hynek Wichterle(Jerry and Emily Spiegel Professor at Columbia University)
Board seatEric Heil· per SEC Form D
BiotechNew York, US
Andrea Spezzi(Executive Officer, Director)
BoardJohn Prufeta(Director)in
Board seatEric Heil· per SEC Form D · $5M raise · filed Sep 2022
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.